Good day to you, ladies and gentlemen, and welcome to the Q1 2014 Geron Earnings Conference Call. My name is Karen, and I'll be your operator for today. [Operator Instructions] And as a reminder, this call is being recorded for training purposes. I'd now like to turn the call over to Anna Krassowska, Head of Investor Relations. Please go ahead.

Thank you, Karen. Good afternoon, everyone, and thank you for joining us for the Geron first quarter 2014 conference call. With me today are: Dr. John Scarlett, our President and Chief Executive Officer; and Olivia Bloom, our Senior Vice President, Finance and Chief Financial Officer. This afternoon, we issued a press release that reported results for the first quarter ended March 31, 2014. This release can be found on our website at www.geron.com. Today's call is also being webcast live on our website and will be available for replay through June 1. Before we begin, please note that except for statements of historical facts, the statements during this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitations, statements regarding the timelines, prospects and plans for imetelstat, including anticipated timelines for submitting data to the FDA to address the clinical hold, the FDA's listing of the clinical hold and clinical study initiation obtaining positive safety data, the therapeutic potential and safety of imetelstat and financial and operational projections or requirements, including spending guidance and any timing of payment of any dividend in connection with the Asterias transaction. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in Geron's periodic reports filed with the Securities and Exchange Commission under the heading Management's Discussion and Analysis of Financial Conditions and Results of Operations, and Risk Factors, including in Geron's quarterly report on Form 10-Q for the quarter ended March 31, 2014. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events and circumstances. We'll begin today's call with a summary of the first quarter operating results from Olivia, and then Chip will review recent events and our beliefs around the timing for initiating new clinical trials for imetelstat. Olivia?

Thanks, Anna. Good afternoon, everyone. For the first quarter of 2014, we reported operating revenues of $474,000 and operating expenses of $9.2 million, compared to $765,000 and $12.8 million, respectively, for the comparable 2013 period. Net loss for the first quarter of 2014 was $8.4 million or $0.06 per share compared to $11.9 million or $0.09 per share for the comparable 2013 period. Revenues for the first quarter of 2014 and '13, included royalty and license fee revenues under various agreements. Interest and other income for the first quarter of 2014 was $83,000 compared to $81,000 for the comparable 2013 period. We expect interest income to be higher in 2014 than in 2013 due to higher cash and investment balances. Research and development expenses for the first quarter of 2014 were $5.2 million compared to $8 million for the comparable 2013 period. The decrease in R&D expenses was primarily the net result of lower personnel-related costs and reduced clinical trial expenses with the wind-down of the imetelstat trials in solid tumors and GRN1005 trials in patients with brain metastases, partially offset by increased manufacturing costs for imetelstat drug product. General and administrative expenses for the first quarter of 2014 were $4 million compared to $4.8 million for the comparable 2013 period. The decrease in G&A expenses primarily reflected reduced patent cost and transaction expenses associated with the closing of the stem cell divestiture in October 2013. We expect G&A expenses to potentially increase during the remainder of the year in connection with the purported class action lawsuits and derivative lawsuit recently filed against the company. We ended the first quarter of 2014 with $153.5 million in cash and investments. We currently expect cash operating expenses for 2014 will be approximately $35 million to $40 million. This guidance assumes initiation of new clinical trials of imetelstat in hematologic myeloid malignancies, such as the Phase II study in patients with MF in the first quarter of 2013, with steady startup costs being incurred in the fourth quarter of 2014, and includes continued manufacturing of imetelstat and support of the myelofibrosis IFT at Mayo Clinic. I will now turn the call over to Chip to provide more detail on plans for further development of imetelstat. Chip?

Thank you, Olivia, and good afternoon, everyone, and thank you for dialing in to our call. As you all know, our IND for imetelstat is presently on full clinical hold, which affected the ongoing company-sponsored studies and has resulted in the remaining patients in the ET and myeloma trials discontinuing treatment. Another consequence of the full clinical hold in our IND is our development plans for imetelstat have been delayed. We announced in March 2013 that we did not intend to develop imetelstat for ET, but instead planned to focus our development plans on imetelstat in hematologic myeloid malignancies with a higher unmet need, such as MF. However, until the every FDA permits us to study such patients, we're unable to submit any new clinical trial protocols to the FDA under our existing IND for imetelstat and are unable to initiate any new clinical trials for imetelstat in the United States. As the basis for this hold, the FDA cited the lack of evidence of reversibility of hepatotoxicity, a risk for chronic liver injury and a lack of adequate follow-up in patients who experience hepatotoxicity. I'll discuss what we need to do to address the full clinical hold on our IND after I discuss the status of Dr. Ayalew Tefferi's investigative-sponsored trial in myelofibrosis. Dr. Tefferi's trial in myelofibrosis, which we call the Myelofibrosis IST, is being conducted at Mayo Clinic under an investigator-sponsored IND, which is separate from Geron's IND. This trial was placed on a partial clinical hold by the FDA shortly after our IND was placed on full clinical hold. The partial clinical hold means that no new patients may be enrolled into the Myelofibrosis IST. The patients who are currently enrolled and were deriving clinical benefit may continue to receive treatment with imetelstat. Dr. Tefferi had…

[Operator Instructions] First question we have comes from Brian Klein from Stiefel. Brian Klein - Stifel, Nicolaus & Company, Incorporated, Research Division: So first on the ET patients. I was wondering if you could give us a quick update and if any of the patients that were previously treated with imetelstat have relapsed?

Excellent question. I don't have data with regard to that. I'm unaware of any, Brian, but I don't have any specific data. Most of them have -- obviously, it's been quite recent that they've come off. Probably most of them, practically speaking, within the last month to 6 weeks. But I don't have any specific information. Good question, though. Brian Klein - Stifel, Nicolaus & Company, Incorporated, Research Division: Okay. And the next, if you could just give us a little bit more color on your plans for ex-U.S. development. What are the gating factors for getting a trial started in Europe? And what other things need to be done in order to get that trial started?

So we're in the early stages of looking at a separate approach in Europe. And of course, we're not at all sure that we need or want to go that approach. So let me say, first of all, that in our original planning for our next myelofibrosis study, we fully intended to include investigators and investigative sites that were in Europe. And we're proceeding apace and those investigators were fully up-to-speed and part of our regular strategy. If, for any reason, we need to actually go down a parallel track, it would mean finding additional investigators in Europe and it would also mean having interactions with regulatory authorities in Europe to determine whether they would feel comfortable pursuing an MF study. So what we're doing right now is we're laying out that strategy. We have not yet had any discussions with such regulators. And of course, we've been in contact with the perspective -- original perspective set of European investigators, but we haven't initiated new investigative sites. So we will be in the process of doing that over the next foreseeable future, I guess, I should say. And if we feel like that is an option that we want to pursue, we will have done the work and then we'll probably talk about that in more detail. But right now, I don't really have a whole lot more to say about it other than we're in planning stages, engaging various consultants and so forth. Brian Klein - Stifel, Nicolaus & Company, Incorporated, Research Division: Okay, great. And then just last question. As we wait for the resolution of the clinical hold, are you looking outside for additional clinical assets to develop? Or do you have any other strategic plans for the company beyond imetelstat?

Well, first of all, let me say that we have a lot of confidence in imetelstat. I think that while we can't be, as we've laid out in the prepared remarks, that we can't be absolutely confident of -- by any means, of timing or ultimate outcomes here. Our principal activities today remain very much focused on imetelstat in hematologic myeloid -- hematologic malignancies with high unmet medical need. Now if we're not able to pursue that, then obviously, that's a very -- or that would be a very major retrenchment. We -- with regard to your specifics about looking elsewhere, we have always been opportunistic and have -- I don't think we've ever stopped looking at other potential aspects or other assets, and we continue to do so today. But we don't have a specific program associated with heightening those activities because we lack confidence in imetelstat or even as just as a backup. Right now, we're really focused on continuing the program with imetelstat. But we are -- we continue to be opportunistic and will be opportunistic as time goes on.

Next question comes from the line of Cory Kasimov of JPMorgan. Whitney G. Ijem - JP Morgan Chase & Co, Research Division: This is actually Whitney, on for Cory today. So quick question. To the extent that you maybe aren't able to get some of the follow-up data from the patients you indicated you kind of have to track some of them down or you might be further out from the study, have you guys talked through that scenario with the FDA? If you do have a certain percent of missing data, is there an amount they're willing to accept there?

No, we haven't talked to any of those scenarios through with the FDA. The way it usually works, and certainly, the way it's working for us is that we make any every possible effort to get every possible scrap of data. And what we have at a certain point will be what we have. And ideally, it will be sufficient. I mean, I don't -- I wouldn't expect anybody would think that we would have every single patient -- every single LFT after they've ended the study. But I think that when we have a quantum of data that allows us to draw some conclusions, we will probably, at that point, prepare a submission, make it and go forward from there. But we haven't actually asked that question because it would be very hard for them to answer it. It's a pretty impossible question to answer, how much is enough. So usually the answer is you do everything you possibly can, send it in and then have a discussion.

The next question comes from the line of Graig Suvannavejh with MLV company. Graig C. Suvannavejh - MLV & Co LLC, Research Division: I've got several. I think on our last call together, there was a question asked about whether you guys had come across any other drugs that have persistent low-grade LFT. And at that time, I don't think you had -- I don't know if there's anything that you've learned since the last time we all gathered that can kind of maybe give you some indication as to whether it was another drug, what happened and kind of what the outcome there was?

Yes, we have obviously gone back and had numerous conversations with a variety of different liver experts in both clinical and pre-clinical. And we still have not seen -- we have still not seen any specifics around drugs that have been identified in this manner, particularly with the low-grade persistent elevations of, for example, [indiscernible]. We haven't seen anything else that's raised a particular concern. There are diseases, Graig, that I should point out that have -- that are not drugs-related that have some of these persistent LFT abnormalities that eventually, after many years, turned into something. But we have not seen any drugs in -- with any specificity. And so I'm afraid we've come -- we haven't found that yet, at least. Graig C. Suvannavejh - MLV & Co LLC, Research Division: Okay. Question -- the next question I have is what kind of outside help have you brought in on a consulting basis to help you out with this process? Or if so, do you feel you have the capabilities in-house? And if you have brought others, what incremental spend on SG&A is that going to contribute to 2014, as far as you can tell at this point?

Okay. I'll do the best I can on the spend part of it, but let me, first of all, characterize the types of help. Probably, from an -- what I'm going to call an intellectual perspective, there's a knowledge, perhaps would be a better way to put it -- a knowledge-based perspective. We've -- obviously, we've indicated, as we commented on in our prepared remarks, several pre-clinical toxicologists and pathologists and regulatory -- pre-clinical regulatory affairs professionals who could look at our prior data as we commonly go and help us think through the possibilities there. The second -- excuse me, the second thing that we've done is we have -- are in the process of engaging some additional scientific experts who could help us lay out a program to look at potential mechanistic approaches to try and to understand if there's anything there or not. We haven't actually spent very money there yet. We've been mostly talking to people and organizing our thoughts around what types of non-clinical models we might put imetelstat in to look at that. The third thing that we've obviously engaged are a group of regulator affairs experts to help us make sure we manage our relationships with the FDA and with external regulatory authorities outside the United States properly. And fourth, we have engaged some additional clinical and clinical operations experts to help us think through what a specific European program might look like, although that's still in its very early ages. I think none of that is terribly extensive, certainly not yet. And some of it matures, we'll have a much better feel and should be able to make a better comment. Olivia, do want to make a comment about this?

Yes, Graig, also what I'll say is that as part of the assumptions that went into the guidance was inclusive of some of the engagement of some of these experts in trying to get a package together for the clinical hold response. Graig C. Suvannavejh - MLV & Co LLC, Research Division: Okay. Just 2 quick questions, if I may. What can you tell about refractory anemia with this ringed sideroblasts, as well as blast-phase myelofibrosis? It's something that's relatively new to me and I'm just trying to gauge what expectations should or should not be around potential ASH '14 data?

So RARS is really quite a interesting and relative -- quite poorly served form of myelodysplastic syndrome. It's one of the MDS syndromes. And in this disease, patients have again presumed underlying progenitor cell clone that results in the fact that they do not make adequate red cells and the vast majority of them become transfusion-dependent. But even if they're not transfusion-dependent, they're always very anemic. The challenge for RARS has been that there are no effective therapies, to our knowledge. Patients, basically, if they do become transfusion-dependent, must rely on transfusions. And so if -- and Dr. Tefferi was very interested in this because there are some characteristics of these patients' clinical presentations that he thought might make them amenable to treatment with imetelstat, and that was, in particular, the ringed sideroblasts. These ringed sideroblasts are a type of cell that you see that's quite common in RARS. And it's relatively uncommon in other hematologic myeloid malignancies, but you see do it occasionally. And he had seen some responsiveness with patients with ringed sideroblasts in the myelofibrosis study. [indiscernible] and go and look in RARS since RARS has no effective treatments today. So I think that the data that you see at ASH should be very interesting to see if this is -- would become the third myeloid hematologic malignancy that imetelstat would have effect in. In fact, I think that would be very interesting. So exciting to see what happens there. Graig C. Suvannavejh - MLV & Co LLC, Research Division: And maybe just a very quick clarifying question and I'll jump back in the queue. Just to reiterate, if you were able -- if the company were able to have the full clinical hold somehow reclassified into a partial clinical hold, that still would not give you the coverage to be able to initiate a new trial. Is that correct or do I have that wrong?

No, not necessarily. I mean, FDA uses a variety of procedural effects or procedures, a variety of procedures to allow sponsors to come to agreement with them about what can and cannot be studied. One mechanism is, obviously, to clear the entire clinical hold and then you go back to sort of where you started. Another mechanism that is possible and it's been utilized many times in the industry, is that a full clinical hold will be converted to a partial clinical hold, usually under very well-defined circumstances. So for example, if we were -- if Dr. Tefferi were to come off of hold and we were -- we felt that we had adequate information to proceed with a myelofibrosis study, we might very well ask the FDA to allow us to do so under a partial clinical hold. That would mean we still wouldn't be able to study ET, but we would be able to study myelofibrosis. That's a theoretical construct, but one that is -- that would not be -- that would have precedent behind it. So I think it's fair to say, Graig, that FDA and sponsors can come to conclusions, based on science and medicine, that make sense for both the safety of patients and the ability to continue to develop drugs where you might have the opportunity to make a real improvement in patient's lives. That's what we're all after here, and FDA are usually very helpful in that manner. So that -- however the process works out, eventually, we would hope to get there.

The next question comes from the line of Roy Buchanan of Piper Jaffray.

Just a few. Has Tefferi indicated or do you guys have any indications how many patients, if any, he's taken off the study?

I don't have that exact information as we speak today. And -- I just don't have it for you, Roy. Sorry.

Okay. And I think Brian asked this, but just to make sure, efficacy updates on the -- from the Tefferi study?

Yes, we -- well, actually, we don't have any efficacy updates per se. Dr. Tefferi and the Mayo Clinic have been very -- as you might imagine, they've been very engaged in responding to the FDA, and that focus has really been on LFT abnormalities and safety-related evaluations. So we have not been talking at all about efficacy. So I don't have any real updates for you.

I know -- I mean, I know it's a gating, but once that gets resolved, it will probably turn back to efficacy.

Yes, I suspect you're right about that.

All right. So I guess -- and this is kind of a speculation, I guess. But if I maybe look too closely at the EHA presentation and the ASH presentation you might be able to discern differences in liver enzyme levels between the 2 patient populations. Am I imagining something there or is there a basis for that? Any comments on that speculation?

So I think that -- I actually have -- I recently looked at the EHA data, but I haven't looked at the ASH presentation recently, so I'm little at a disadvantage. I don't have it in front of me. But if we -- if I -- I think what you would say was that there -- it was your there point that there was higher incidence of LFT abnormalities reported at EHA compared to what Dr. Tefferi reported in his study?

Yes. So there's one Grade II hyperbilirubinemia in the ASH presentation, no AST, no ALT. He could have just left it out, but...

Yes. So I think there are a couple of comments -- I think there are couple of comments to be made. First of all, that -- first of all, in the ASH presentation, which, as I recall, was among the N of equal to 33 patients. This is Dr. Tefferi's ASH presentation. He had, as you said, 2 patients who had a Grade 2 hyperbilirubinemia and did not have any patients that were reported, at that time, at least, with Grade 3 or above hyperbilirubinemia. And there were no obvious patients with other LFT abnormalities. I would comment that, number one -- and that was quite different that the EHA presentation. Still, no Grade 3 or Grade 4 LFT abnormalities associated with the ET study -- sorry, no Grade 4. There were a couple of Grade 3 ALTs and 1 AST and no Grade 3 or Grade 4 [indiscernible]. I think the really big difference in these studies was, first of all, that the EHA data, that was a data cut of around May of 2013. And I don't recall the exact number of months on average that patients had been treated. But it was up to -- roughly up to 2.5 years and on average, around 14 months, if memory serves me correct. And so that's a really quite a bit of longer than Dr. Tefferi have been studying patients. And of course, remember also that the EHA data for sure was everything that was reported regardless of attribution et cetera, and regardless of baseline data. So I think it is certainly possible that there will be differences on a -- from individual disease basis. And it's certainly possible that there may be, for example, a different level of baseline abnormalities. For example, in myelofibrosis, we know that in myelofibrosis, patients have extramedullary hematopoiesis. That is their bone marrow isn't working and so they push out their production of red cells and white cells and so forth to the liver and spleen. And so they may have a much higher incidents of baseline abnormalities, and some of those may go away. So I think it's -- we're just speculating now. I think it's a little too hard to make a real firm comment about the differences in myelofibrosis patients versus ET in the reactions to imetelstat. It's too much apples and oranges at this point.

Okay. And you probably just answered my next question, but the -- I was going to ask what's the typical baseline liver enzyme levels for an ET and/or MF patient? Is -- and if there's any meaningful level of baseline risks for the patients?

Yes. So part of the analysis that's being done right now is to look at, if you will, shift tables and so forth, to look at what happens to the patients who have baseline abnormalities. Do they get worse? Do they disproportionally get worse? Do they get better? Because in treatment of some of these disorders, we would absolutely expect some of these patients with baseline LFT abnormalities, particularly in myelofibrosis. If we're actually making a big dent in the disease, we would expect that they -- many of them might get better. I think Dr. Tefferi's data, when it finally does come out, it's going to be very instructive. We just -- we don't know right now. It's a little speculative. But there will be, I can almost assure you, baseline abnormalities, and what happens to them will be very interesting and important.

That you for your questions. I would now like to turn the call over to Dr. John Scarlett, CEO, for closing remarks.

Well, thank you. This went on a long time. I thank all of you for your continued interest, both in the drug and the company, and for joining us today. And we look forward to having more information for you and being able to share that with you. Thanks a lot, everybody. Have a good day.